Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Any severe or serious AE (grade 3, 4 or 5) · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any severe or serious AE (grade 3, 4 or 5) compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 1 [0.8, 1.27]Studies not reportedLow